What Disqualifies You From Receiving an Organ Transplant?

No single medical condition automatically bars every patient from every type of organ transplant. Transplant programs evaluate candidates individually, weighing expected survival benefit against surgical risk, and what counts as a disqualification at one hospital may be treated as a manageable obstacle at another. That said, certain medical, behavioral, and psychosocial factors consistently make listing difficult or impossible, and understanding them can help you navigate an opaque system or advocate for someone who is being evaluated.

Why There Is No Universal List of Disqualifications

One of the most frustrating realities of the transplant system is that eligibility criteria vary from center to center and from organ to organ. A national survey of adult and pediatric heart, kidney, liver, and lung programs in the United States found wide differences in what programs treat as absolute contraindications. For example, roughly 90% of heart and lung programs considered a body mass index above 45 an absolute bar to listing, but only about half of liver programs did. Age over 80 was an absolute contraindication at about 84% of heart programs but only 29% of kidney programs.

¹

This variation means that being turned down at one center does not necessarily mean you have been permanently disqualified. It may mean that center’s policies are stricter on a particular factor, or that a different transplant team would weigh your circumstances differently. Still, several categories of concern come up repeatedly across programs.

Active or Untreatable Cancer

An active malignancy is one of the closest things to a universal disqualification. Because transplant recipients must take immunosuppressive drugs for the rest of their lives, and those drugs dampen the immune system’s ability to fight cancer, placing an organ in someone with active cancer risks accelerating tumor growth and wasting a scarce organ. The calculation gets more nuanced once a cancer has been treated. Programs generally require a cancer-free interval before listing, but how long that interval needs to be depends on the type of cancer, its stage at diagnosis, and how it was treated. Cancer recurrence after transplant carries a high mortality rate, so clinicians weigh whether the survival benefit of transplantation outweighs the risk of recurrence under immunosuppression.

²

For some low-risk cancers, the required wait may be as short as two years. For others, programs may want five years or more of clean follow-up. There is no single national standard, and this is one of the areas where getting a second opinion at a different transplant center can genuinely change your outcome.

Severe Cardiovascular Disease

Heart disease is the leading cause of death among patients with advanced kidney disease and among kidney transplant recipients. Before listing you for a kidney (or most other organs), a transplant team will perform a cardiovascular workup to screen for problems like blocked coronary arteries, severe heart failure, or significant valve disease. The goal is to identify conditions that might make you unlikely to survive the surgery itself or the early post-transplant period.

³

This does not mean that any heart problem is disqualifying. If a blocked artery can be stented or if heart failure can be stabilized with medication, many programs will proceed. The question is whether your cardiovascular risk is so high that a transplant would do more harm than good. For heart transplant candidates specifically, the evaluation flips: your heart is the organ being replaced, so the team instead focuses on whether your other organs, lungs, liver, and kidneys, are healthy enough to withstand the procedure.

Active Infections

Certain infections in the period immediately before transplant may require delaying the procedure. This makes intuitive sense: the surgery itself is a major physical stress, and the immunosuppressive drugs you will start taking right afterward will weaken your ability to fight infection. Going into transplant with an active bloodstream infection, uncontrolled tuberculosis, or certain untreated viral infections can be dangerous.

⁴

HIV is worth mentioning specifically because the landscape has shifted dramatically. In the era before effective antiretroviral therapy, HIV was almost universally considered an absolute contraindication. That is no longer the case. The same national survey that documented wide variation across programs found that only about 30% of adult programs still treat HIV as an absolute bar to listing. For kidney programs specifically, that figure was under 17%.

¹

Alcohol, Tobacco, and Other Substance Use

Substance use policies are among the most debated areas in transplant eligibility. The most well-known rule is the six-month alcohol abstinence requirement for liver transplant candidates, sometimes called “the six-month rule.” Most programs require patients with alcohol-related liver disease to demonstrate at least six months of sobriety before being listed. The rationale is that a longer period of sobriety predicts a lower likelihood of relapse after transplant.

⁵

The problem is that this rule can effectively be a death sentence. Many patients with severe acute alcoholic hepatitis who do not respond to medical treatment will not survive the six-month waiting period. Research has shown that carefully selected patients transplanted earlier can achieve excellent survival outcomes, which has pushed some centers to relax or abandon the rigid six-month rule in favor of more individualized assessments of relapse risk.

⁶

Tobacco use follows a similar pattern. The International Society for Heart and Lung Transplantation treats active smoking within six months of transplant as a relative contraindication. However, research suggests that a six-month abstinence period does not fully eliminate the increased risks associated with a smoking history. Former smokers still show worse post-transplant outcomes compared to people who never smoked.

⁷

Cannabis is an increasingly contentious issue. As more states legalize cannabis, transplant programs are grappling with inconsistent policies. Some centers still treat any cannabis use as disqualifying, while others have relaxed their stance. This inconsistency, combined with clinician biases, has the potential to worsen racial and regional disparities in who gets listed and who does not.

⁸

Psychosocial Evaluation and Social Support

Every transplant evaluation includes a psychosocial assessment, and the results can be decisive. A national survey of transplant providers found that, on average, programs excluded about 10% of evaluated patients in the prior year due to inadequate social support.

⁹

The reasoning is practical: post-transplant care is demanding. You need someone to drive you to frequent appointments, help manage a complex medication schedule, watch for signs of rejection, and assist with daily tasks during recovery. Programs worry that without a reliable caregiver, your chances of a good outcome drop significantly. Whether this is a fair criterion or a barrier that disproportionately punishes people who are isolated, low-income, or lack traditional family structures is a live ethical debate in the field.

Psychiatric illness adds another layer. Data from the 1990s indicated that a majority of transplant programs considered certain psychiatric conditions, such as active schizophrenia, to be absolute contraindications. Limited evidence since then suggests that psychiatric illness continues to be used as a reason to deny transplant at some centers, even though comprehensive updated data on the topic is lacking.

^{10 11}

The concern is typically about whether a person can reliably take immunosuppressive medications and keep follow-up appointments. But critics argue that well-managed psychiatric conditions should not be treated the same as uncontrolled ones, and that blanket exclusions amount to disability-based discrimination.

Age, Frailty, and Physical Reserve

Advanced age is not an automatic disqualification in most programs, but it does raise the bar. As noted earlier, age over 80 is treated as an absolute contraindication by a majority of heart and lung programs, but kidney programs are much more permissive on age alone. The trend in transplant medicine is to move away from rigid age cutoffs and toward assessments of biological fitness.

Frailty, a clinical concept encompassing weakness, slowness, low physical activity, and exhaustion, turns out to be a better predictor of post-transplant outcomes than age by itself. Many lung transplant candidates, for example, are older and frailer than in previous decades, and older patients are at increased risk for death before and after transplant. But that risk is not explained by numerical age alone.

¹²

Researchers and transplant experts have argued that general chronological age limits are problematic and that individual functional assessment, incorporating geriatric tools that measure how well a patient can actually perform daily tasks, would be more accurate and more fair.

¹³

Immunological Sensitization

Some patients have immune systems that are primed to attack a wide range of donor tissues. This happens when your body has been exposed to foreign tissue through previous transplants, blood transfusions, or pregnancy. Programs measure this through a panel-reactive antibody test, which indicates what percentage of the donor population your antibodies would react against.

Patients at the extreme end of sensitization face a real practical barrier. Among the most highly sensitized kidney candidates, about three-quarters were predicted to be compatible with an average of only six deceased donors in the entire system. The remaining quarter appeared to be incompatible with every deceased donor organ entering the system.

¹⁴

This is not technically a disqualification, because you can still be listed and wait for a compatible organ. But it can mean years on the waitlist, and some patients never find a match. Desensitization treatments exist to lower antibody levels, but they are expensive, not always effective, and not available at every center.

Financial and Insurance Barriers

Transplant programs do not publicly advertise “ability to pay” as a listing criterion, but the reality is that financial concerns can effectively block access. The cost of immunosuppressive drugs alone is substantial, and for patients without long-term insurance coverage, the out-of-pocket expense may be unaffordable.

¹⁵

Programs sometimes ask about your insurance status and financial resources during the evaluation. The concern is legitimate on one level: if you cannot afford your anti-rejection medications after transplant, you will likely lose the organ. But this means that a person’s wealth, or lack of it, can become a de facto disqualification, raising serious equity questions. Some patients resort to fundraising campaigns just to demonstrate financial readiness.

Disability and Developmental Delay in Children

How transplant programs handle intellectual and developmental disability is one of the most ethically fraught areas in the field. A survey of major pediatric transplant centers found that 43% of programs “always” or “usually” consider neurodevelopmental delay in their listing decisions, while 39% said they “rarely” or “never” do. About 14% of programs treated even mild or moderate delay as a relative contraindication, while 22% reported that developmental delay was irrelevant to the listing decision. Strikingly, no programs described their decision-making process as “formal, explicit, and uniform.”

¹⁶

Federal laws including the Americans with Disabilities Act and Section 504 of the Rehabilitation Act are supposed to protect people with disabilities from discrimination, but analysis suggests these laws have made little progress toward preventing disability-based discrimination in organ transplant evaluation specifically.

¹⁷

How Much Depends on Where You Are Evaluated

The center-to-center variation in eligibility standards is not a minor detail. It is a defining feature of the transplant system. A study examining simultaneous heart-kidney transplantation found that, after adjusting for patient characteristics, the odds of receiving that combined transplant varied 57-fold between the highest- and lowest-performing centers. Among patients on dialysis who underwent heart transplant, the rate at which they also received a kidney ranged from 22% to 86% depending on the center.

¹⁸

That kind of variation means your outcome can depend as much on geography and institutional culture as on your medical condition. Broader justice concerns compound the problem. Disparities in who gets referred for transplant evaluation in the first place, and which patient groups face barriers to even getting on waiting lists, mean the system’s inequities start well before the formal eligibility decision.

¹⁹

Vaccination Requirements and Emerging Policy Battles

The COVID-19 pandemic introduced a new front in transplant eligibility debates. Numerous transplant centers began requiring COVID-19 vaccination as a condition of remaining active on the waiting list. One center’s experience proved revealing: patients from the most disadvantaged zip codes had nearly twice the odds of being inactivated for not meeting the vaccination requirement, and those on Medicaid had nearly three times the odds compared to commercially insured patients.

²⁰

These findings highlighted how well-intentioned public health requirements can inadvertently create new barriers that fall hardest on already vulnerable populations. The broader lesson applies beyond COVID-19 vaccines: whenever a transplant program adds a new eligibility requirement, there is a real risk that the burden of compliance will not be distributed equally. Programs are increasingly being pushed to think about equity implications when writing these policies, though how far that thinking has translated into changed practices varies widely.